Topics
Business & Finance
-
Friday - April 3, 2009
Realignment of biotech research activities:
Bayer CropScience to consolidate European Plant Biotechnology Research in Ghent
Focus to lie on stress tolerance, increasing yields and optimized quality traits in plants in future
-
Tuesday - March 31, 2009
Bayer HealthCare and Genzyme Corporation Enter New Strategic Agreement
Agreement improves profitability and strategic focus in key Bayer therapeutic areas / Licenses hematological cancer products to Genzyme / Continues co-development partnership for alemtuzumab in multiple sclerosis (MS) / Bayer maintains worldwide co-promotion rights for alemtuzumab in MS – distribution rights returned to Genzyme / Bayer to receive substantial licensing, milestone payments from Genzyme over the duration of the agreement
-
Tuesday - March 31, 2009
Company strengthens its crop protection portfolio:
Bayer CropScience has acquired certain AgroGreen´s biological products for the crop protection business
-
Thursday - March 26, 2009
Bayer MaterialScience builds new manufacturing facility for polyurethane raw materials in India
20 Million Euro investment underlines growth strategy in the region / New plant in Ankleshwar to produce Desmodur® polyisocyanates from 2011
-
Monday - March 23, 2009
Bayer issues corporate bond with a volume of EUR 1.3 billion
-
Thursday - March 19, 2009
Venous Blood Clot Prevention after Hip or Knee Replacement Surgery:
U.S. FDA Advisory Committee supports favorable benefit-risk profile of Bayer’s rivaroxaban
-
Tuesday - March 3, 2009
Spring Financial News Conference
Full Year 2008 Results
-
Friday - February 27, 2009
Bayer proposes increased dividend for 2008 of EUR 1.40 per share
Plans to switch from bearer shares to registered shares
-
Thursday - February 12, 2009
Bayer Schering Pharma to invest 100 million Euro in China to build a global R&D center
-
Friday - January 30, 2009
Subgroup makes use of opening clause in collective agreement
Bayer MaterialScience reduces work week
Temporary worktime reduction of 6.7 percent with corresponding pay adjustment / Cuts for managerial employees as well / Time freed up to be used for continuing education measures
-
Friday - January 23, 2009
Bayer MaterialScience in talks with employee representatives on the introduction of short-time working
-
Wednesday - January 7, 2009
Visanne® - new long-term treatment for endometriosis submitted for registration in Europe
-
Monday - December 8, 2008
Venous Blood Clot Prevention after Knee or Hip Replacement Surgery:
Xarelto® Reduces Symptomatic VTE and Death Following Knee or Hip Replacement Surgery by More Than 50% Compared to Enoxaparin in Pooled Analysis of RECORD Clinical Trial Program
Pooled Analysis of RECORD1-4 Trials Confirms Significant Benefit in Clinical Outcomes for Patients Treated with Xarelto / RECORD4 Study Demonstrates Xarelto is the Only Oral Anticoagulant to Show Clinical Benefit in Head-to-Head Comparison Against U.S.-Approved Regimen of Enoxaparin
-
Friday - December 5, 2008
Daniel Hartert to be new Executive Board Chairman of Bayer Business Services GmbH
-
Tuesday - November 25, 2008
Bayer Healthcare llc Reaches Settlement with U.S. Department of Justice on Investigation into former Diabetes Care Marketing Programs
Corporate Integrity Agreement to cover Bayer HealthCare Diabetes Care, Bayer HealthCare Pharmaceuticals, Medrad (including Possis), Intendis and Viterion TeleHealthcare
Search
Publications
Stockholders' Newsletter
Annual Report
Sustainable Development Report
The Bayer Climate Program
research – The Bayer Scientific Magazine
Publications Overview
Newsletter
EventsFriday, February 26, 2010
Annual Report 2009 / Financial News Conference Full Year 2009
Contact: Günter Forneck
Additional Press Events
Investor Relations Events
Sport Events
BayKomm Events
Download Center - Selection